MX2023010825A - Metodos para tratar el cancer con anticuerpos anti-ilt3. - Google Patents
Metodos para tratar el cancer con anticuerpos anti-ilt3.Info
- Publication number
- MX2023010825A MX2023010825A MX2023010825A MX2023010825A MX2023010825A MX 2023010825 A MX2023010825 A MX 2023010825A MX 2023010825 A MX2023010825 A MX 2023010825A MX 2023010825 A MX2023010825 A MX 2023010825A MX 2023010825 A MX2023010825 A MX 2023010825A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen binding
- metastatic
- methods
- treating cancer
- ilt3
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 230000001394 metastastic effect Effects 0.000 abstract 4
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 abstract 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 208000010979 non-small cell squamous lung carcinoma Diseases 0.000 abstract 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 abstract 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta divulgación se refiere a métodos para tratar tumores sólidos en un paciente identificado por tener cáncer de mama triple negativo metastásico, glioblastoma, adenocarcinoma ductal pancreático metastásico, sarcoma de tejido blando metastásico o carcinoma de pulmón no microcítico no escamoso metastásico, que comprende administrar una proteína de unión a antígeno anti-ILT3, o fragmento de unión a antígeno, y una proteína de unión a antígeno anti-PD1, o fragmento de unión a antígeno, al paciente cada tres semanas (Q3W).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163163779P | 2021-03-19 | 2021-03-19 | |
PCT/US2022/020714 WO2022197900A1 (en) | 2021-03-19 | 2022-03-17 | Methods for treating cancer with anti-ilt3 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023010825A true MX2023010825A (es) | 2023-12-08 |
Family
ID=83320983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023010825A MX2023010825A (es) | 2021-03-19 | 2022-03-17 | Metodos para tratar el cancer con anticuerpos anti-ilt3. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4308243A1 (es) |
JP (1) | JP2024511977A (es) |
KR (1) | KR20230158057A (es) |
CN (1) | CN117412771A (es) |
AU (1) | AU2022239502A1 (es) |
BR (1) | BR112023018921A2 (es) |
CA (1) | CA3212604A1 (es) |
MX (1) | MX2023010825A (es) |
WO (1) | WO2022197900A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7194481B2 (ja) * | 2017-11-17 | 2022-12-22 | メルク・シャープ・アンド・ドーム・エルエルシー | 免疫グロブリン様転写産物3(ilt3)に特異的な抗体およびその使用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3570840A1 (en) * | 2017-01-20 | 2019-11-27 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
JP7194481B2 (ja) * | 2017-11-17 | 2022-12-22 | メルク・シャープ・アンド・ドーム・エルエルシー | 免疫グロブリン様転写産物3(ilt3)に特異的な抗体およびその使用 |
EP3790895A4 (en) * | 2018-05-10 | 2022-05-11 | The Regents of the University of California | CCL21 AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER |
-
2022
- 2022-03-17 BR BR112023018921A patent/BR112023018921A2/pt unknown
- 2022-03-17 KR KR1020237035228A patent/KR20230158057A/ko unknown
- 2022-03-17 JP JP2023556755A patent/JP2024511977A/ja active Pending
- 2022-03-17 MX MX2023010825A patent/MX2023010825A/es unknown
- 2022-03-17 AU AU2022239502A patent/AU2022239502A1/en active Pending
- 2022-03-17 WO PCT/US2022/020714 patent/WO2022197900A1/en active Application Filing
- 2022-03-17 EP EP22772190.9A patent/EP4308243A1/en active Pending
- 2022-03-17 CA CA3212604A patent/CA3212604A1/en active Pending
- 2022-03-17 CN CN202280036448.1A patent/CN117412771A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN117412771A (zh) | 2024-01-16 |
AU2022239502A9 (en) | 2024-02-22 |
JP2024511977A (ja) | 2024-03-18 |
EP4308243A1 (en) | 2024-01-24 |
BR112023018921A2 (pt) | 2023-12-05 |
CA3212604A1 (en) | 2022-09-22 |
KR20230158057A (ko) | 2023-11-17 |
WO2022197900A1 (en) | 2022-09-22 |
AU2022239502A1 (en) | 2023-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
BR112019010356A2 (pt) | molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo | |
MY202279A (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
MX2011010469A (es) | Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer. | |
MXPA03001634A (es) | Polipeptido tumoral cripto. | |
MX2010003766A (es) | Composicion para el tratamiento de cancer pulmonar, en particular canceres pulmonares no microciticos (cpnm). | |
WO2003048328A3 (en) | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen | |
SG160412A1 (en) | Anti-igfr1 antibody therapeutic combinations | |
TR200003879T2 (tr) | İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ | |
TW201129380A (en) | Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1 | |
EA200970607A1 (ru) | Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования | |
UA99601C2 (ru) | Применение антитела к cd151 для лечения первичных опухолей | |
MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
MX2023010825A (es) | Metodos para tratar el cancer con anticuerpos anti-ilt3. | |
MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
EP1968981A4 (en) | METHOD FOR TREATING TUMORS WITH AZAXANTHONES | |
CY1108194T1 (el) | Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων | |
MX2019009121A (es) | Antcuerpos anti-kaag1 o fragmento de union al antigeno del mismo para el tratamiento de cancer de mama triple negativo. | |
MX2022005345A (es) | Terapia de combinación para el tratamiento de cáncer cerebral. | |
DE60038624D1 (de) | Methoden zur behandlung von festen tumoren und metastasen mit gentherapie | |
IL218442A0 (en) | Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma | |
MX2024001363A (es) | Metodos para el tratamiento de la leucemia mieloide aguda con los anticuerpos anti-ilt3. | |
WO2023034336A3 (en) | Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility | |
MX2022000853A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer. |